Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20210189
    Release date: 3 August 2021

    Promoter – Financial Intermediary




    Priothera is a clinical stage company developing receptor modulators for haematologic malignancies, i.e. cancers that affect blood, bone marrow, and lymph nodes (e.g. leukaemia). Priothera is developing a novel drug, mocravimod for acute myeloid leukaemia (AML) with an aim of enhancing the curative potential of Hematopoietic Stem Cell Transplantation (HSCT).

    Additionality and Impact

    The project concerns a venture debt operation under the European Guarantee Fund. The purpose of the loan is to provide direct equity-type financing under EIB's Venture Debt Instrument to bridge the liquidity need of the innovative company 'Priothera', an SME based in Ireland, which has been impacted by the Covid-19 pandemic. The company is a small growth stage research-based pharma SME, developing solutions for haematological cancers. The financing of this project addresses the failure in financial markets for RDI-driven SMEs, arising from their limited access to financing as a result of factors such as information asymmetries, misalignment of incentives etc. Creation of knowledge and support of skilled jobs in Ireland will further contribute positively towards the EU's 3% RDI intensity target. Hence, EIBs involvement in this project supports the development of an innovative medicinal product with important health benefits, which would otherwise have been significantly delayed due to the Covid-crisis.


    The proposed transaction will support research and development (R&D) investments that are required in order to advance the clinical development of an innovative product in indications that address a high unmet medical need. By co-investing in the project, the Bank contributes to improving healthcare, whilst also fostering the generation of European scientific knowledge and acumen, preserving and cultivating highly skilled employment opportunities. Developing orally applied receptor modulators for hematologic malignancies, i.e. cancers that affect the blood, bone marrow, and lymph nodes, commonly known as leukaemia.


    Priothera is a clinical stage, pre-revenue company developing orally applied receptor modulators for haematologic malignancies, i.e. cancers that affect the blood, bone marrow, and lymph nodes, commonly known as leukaemia. As a first indication Priothera is targeting Acute Myeloid Leukaemia (AML), which is the most common form of leukaemia. It is a rare and severe disease, and therefore, classified as an orphan disease.


    • Services - Professional, scientific and technical activities

    Proposed EIB finance (Approximate amount)

    EUR 18 million

    Total cost (Approximate amount)

    EUR 48 million

    Environmental aspects

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.


    The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority; thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.


    Signed - 18/11/2021


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Ireland Services